Tuesday, September 06, 2016 6:05:25 PM
http://www.nasdaq.com/symbol/cycc/short-interest
https://www.thestreet.com/story/13674061/1/cyclacel-pharmaceuticals-cycc-stock-pops-h-c-wainwright-bullish.html
http://globenewswire.com/news-release/2016/09/06/869615/0/en/Cyclacel-s-CYC065-Demonstrates-Promising-Activity-in-MYCN-Addicted-Neuroblastoma-in-Preclinical-Data-Presented-at-Childhood-Cancer-2016.html
http://www.cyclacel.com/
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.
Our Pipeline
Applying its core strength in cell cycle biology, Cyclacel is advancing a pipeline of orally available, small molecule, investigational drugs designed to stop uncontrolled cell division. Sapacitabine, our lead drug candidate, is being evaluated in the SEAMLESS pivotal Phase 3 trial in elderly patients with acute myeloid leukemia under a Special Protocol Assessment agreement with the US Food and Drug Administration. For more information on our investigational drug programs and clinical trials, please go to the Research & Development tab above.
Learn more about our clinical trials:
Sapacitabine (CYC682)
An oral nucleoside analogue prodrug that acts through a novel mechanism.
Seliciclib (CYC202)
A novel, first-in-class, orally available, cyclin dependent kinase (CDK) inhibitor.
CYC065
A highly-selective, orally-available, 2nd generation inhibitor of cyclin dependent kinases (CDK) 2 and 9.
Recent CYCC News
- Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/19/2024 08:05:00 PM
- US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat • IH Market News • 03/19/2024 11:27:29 AM
- Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/13/2024 08:05:00 PM
- Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 • GlobeNewswire Inc. • 03/07/2024 02:15:00 PM
- Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit • GlobeNewswire Inc. • 03/06/2024 02:15:00 PM
- Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/20/2024 02:15:00 PM
- Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer • GlobeNewswire Inc. • 01/30/2024 02:15:00 PM
- Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions • GlobeNewswire Inc. • 12/18/2023 02:00:00 PM
- Cyclacel Pharmaceuticals Announces Reverse Stock Split • GlobeNewswire Inc. • 12/12/2023 09:05:00 PM
- Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC • GlobeNewswire Inc. • 11/30/2023 02:15:00 PM
- Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q • GlobeNewswire Inc. • 11/28/2023 10:15:00 PM
- Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/07/2023 02:15:00 PM
- Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/09/2023 08:05:00 PM
- Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results • GlobeNewswire Inc. • 08/03/2023 01:15:00 PM
- Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/11/2023 08:05:00 PM
- Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results • GlobeNewswire Inc. • 05/04/2023 01:15:00 PM
- Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit • GlobeNewswire Inc. • 05/03/2023 01:15:00 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM